Thank you for the opportunity to provide expert advice on the Draft Research Plan on Screening for Peripheral Artery Disease.
|
|
- August McDowell
- 5 years ago
- Views:
Transcription
1 January 12, 2012 Robert L. Cosby, Ph.D., MSW Senior Coordinator, USPSTF Department of Health and Human Services Agency for Healthcare Research and Quality Center for Primary Care, Prevention and Clinical Partnerships (CP3) 540 Gaither Road, Suite 6143 Rockville, MD Dear Dr. Cosby: Thank you for the opportunity to provide expert advice on the Draft Research Plan on Screening for Peripheral Artery Disease. As is known to Congress, NHLBI, and many public health advocacy groups, the evidence base now robustly clarifies that peripheral artery disease represents one of the most common, under-diagnosed, morbid, and mortal of all cardiovascular diseases in the United States. It is common in patients with diabetes and, in contrast to PAD in nondiabetic individuals, it is more prevalent and more commonly asymptomatic. (1) As the tools of evidence-based medicine are best applied within a well-crafted public health context, our comments are intended to provide the Task Force with an efficient and accurate approach to this critical cardiovascular public health topic. This response is provided to enhance your approach to the specific elements of the plan that were released on December 15, Proposed Analytic Framework According to the proposed analytic framework, the US Preventive Services Task Force intends to use an unselected sample of asymptomatic adults to evaluate the effectiveness of ABI screening to improve clinical outcomes for individuals with lower extremity atherosclerotic PAD. We note that there is no scientific rationale for USPSTF to consider an analysis that focuses on application of any atherosclerosis diagnostic method to an unselected adult population. As for nearly all diagnostic approaches for cardiovascular diseases of adults, the research plan should focus only on adults aged 65 years and older. This cohort has been extensively studied, and the accuracy, efficiency, and safety of PAD detection in this population verified in the evidence base. (2-5) 1
2 Numerous independently funded, population-based studies have demonstrated that PAD prevalence increases with age. This evidence base demonstrates that PAD is very efficiently detected in individuals over 65 years, and this diagnosis has major impact for Americans who do not have prior evidence of atherosclerosis. Evaluation of a population less than 65 years of age is unlikely to be helpful. (6-10) The Framingham Heart Study had by 1970 described the high prevalence of lower extremity PAD in this classic epidemiologic population by assessing the prevalence of claudication as a symptomatic marker of PAD prevalence. The Framingham investigators, and all investigations published since then, have noted that the claudication cohort represented a very small fraction of the total population with PAD. This large cohort study of 2,336 men and 2,873 women between the ages of 28 and 62 years, who were initially assessed at standardized examinations every 2 years since 1948, documented the age-dependent prevalence of PAD. Later studies found that the agespecific annual incidence of intermittent claudication for ages 30 to 44 years was 6 per 10,000 men and 3 per 10,000 women. This incidence increased ten-fold, to 61 per 10,000 men, and nearly twenty-fold, to 54 per 10,000 women, among individuals between the ages of 65 and 74 years. (11-12) In the 1980s, Criqui and colleagues evaluated the prevalence of PAD in epidemiologic evaluation of a free-living asymptomatic population of 613 men and women. The use of objective noninvasive ABI and pulse-wave velocity techniques defined the prevalence of lower extremity PAD to be 2.5% among individuals 60 years and younger, 8.3% among those aged 60 to 69 years, and 18.8% among those 70 years and older (13). These data, and an extensive evidence base accumulated since then, have also clarified that the largest burden of PAD is present in individuals without recognized limb ischemic symptoms. In the 1990s, two large prospective epidemiologic assessments have re-demonstrated a high prevalence of PAD in community-derived individuals. Diehm and colleagues evaluated 6,880 unselected patients in 344 primary-care offices with an entry criteria of age greater than 64 years and a life expectancy of > 6 months. In this cohort, 18% of subjects had PAD, and most subjects did not have any recognizable symptoms. (14) Similarly, Hirsch and colleagues evaluated 6,979 subjects in 350 primary care practices across the United States, performing an ABI in subjects between the ages of 50 and 69 years with a history of smoking or diabetes, or older than 70 years. In this cohort, PAD was detected in 29% of the study population and less than 12% of individuals so detected had classic claudication symptoms. (15) In the past, the Task Force has developed age-specific recommendations. For example, in 2011, clinical guidelines to screen adults for hearing loss were based on a baseline age of 50 years or older. In 2010, guidelines for reducing falls in older adults were based on an age of greater than 70 years. In 2009, recommendations on the use of folic acid in women were directed at the vulnerable child-bearing age and visual acuity guidelines are also obviously directed at gaining the clinical benefit that accrues when such preventative recommendations are applied to older Americans. The Task Force has also developed 2
3 recommendations examining the benefits of breast and prostate cancer screening in selected age-based population cohorts. PAD is now widely known to represent one of the most important atherosclerotic syndromes. Non-detection and non-treatment permit disease to progress in a large untreated population and thus individuals suffer preventable heart attack, stroke and, to a lesser degree, amputation. In this context, it is imperative that the Task Force focus its evaluation of the evidence base that demonstrates that PAD is a disease of older Americans. We strongly recommend that the US Preventive Services Task Force limit its examination on the benefits of ABI screening to individuals age 65 and older. Key Question #1: Does screening for peripheral artery disease (PAD) with an ankle brachial index (ABI) in asymptomatic adults lead to reduced mortality, reduced morbidity from PAD (e.g., onset of symptoms, amputation, impaired ambulation, impaired function), or reduced cardiovascular morbidity (e.g., myocardial infarction, stroke)? [Does the effectiveness of screening for PAD vary by subgroup (i.e., age, sex, race, risk factors)?] We note that the effort by the Task Force to bundle disparate screening efficacy outcomes into a single question may create methodologic challenges. The current question could best be divided into specific queries. The evidence base that has evaluated improved cardiovascular event reduction benefits is strong. The evidence base that has evaluated potential claudication improvement is less robust. The evidence base for amputation prevention in unselected adult populations is weak. The evidence base for mortality reduction is poor. USPSTF may sustain its methodologic efficacy within the now very large PAD published database by assuring its focus on clinical questions where the most evidence exists with potential to achieve the greatest positive public health impact. Key Question #2: What is the diagnostic accuracy (e.g., sensitivity, specificity, positive predictive value, negative predictive value) of ABI as a screening test for PAD in asymptomatic adults? [Does the diagnostic accuracy of ABI screening vary by subgroup (i.e., age, sex, race, risk factors)]? We note that the work of the Task Force may be facilitated, as is true for all evidencebased assessments, by expanding the data source and method and securing access to high quality sources that are not yet available in the indexed citation sources. The American Heart Association, for example, has completed a multiyear evaluation of the diagnostic accuracy of the ABI via its Scientific Statement process (e.g., The Measurement and Interpretation of the Ankle-Brachial Index: A Scientific Statement from the American Heart Association ). This manuscript contains a careful analysis of the evidence derived by careful review of over 210 published references, and that is summarized in 10 tables and figures. This source could be provided upon request. USPSTF should seek evidence from additional 3
4 health professional organizations with expertise in this topic and with access to additional information not currently available in the indexed citation sources. Key Question #3: What are the harms of screening (e.g., overdiagnosis, overtreatment)? Do the harms of screening vary by subgroup (i.e., age, sex, race, risk factors)? Based upon on our comprehensive review of the medical literature, we note that the published evidence base contains absolutely no evidence to demonstrate that screening for peripheral artery disease causes harm to patients. We are, however, concerned that the Task Force may, as it appeared to do in 2005, hypothesize about theoretical harms that were not supported by evidence. Specifically, the Task Force wrote that: [p]otential harms of screening include false-positive results, labeling, and the adverse events associated with an angiographic workup, including contrastrelated events, arterial perforations, hematomas, thromboses, and distal embolizations. We note that the use of conjecture and speculation is not an evidence-based methodology. Use of speculative harms in such a method would also permit use of speculative benefits. Thus, the Task Force should use the same evidence requirements for the demonstration of harm that it uses for the confirmation of benefit and avoid the use of anecdote and nonliterature-based inference. Key Question #4-B: Does treatment of PAD in asymptomatic adults lead to improved patient outcomes beyond the benefits of treatment in symptomatic adults, or beyond the benefits of treatment in persons with identified conventional risk factors alone (i.e., diabetes, smoking, hypertension, hyperlipidemia)? Does the effectiveness of earlier treatment of PAD vary by subgroup (i.e., age, sex, race, risk factors)? We would ask that this Key Question be made more specific and more relevant. First, as the USPSTF work frame is that of prevention, comparison of diagnostic and treatment interventions in asymptomatic patients to those with symptoms is not relevant. The evidence of the diagnostic and treatment efficacy for individuals with symptomatic PAD (e.g., classic claudication or critical limb ischemia) is proven. We believe that the Task Force is addressing the following key questions: (a) Is there a benefit to identifying and treating patients prior to their presentation with leg symptoms? (b) Is there a benefit to treating patients beyond what atherosclerosis risk factor modification alone would mandate? We note that this second question poses another serious conjectural comparison, as it assumes that clinicians perform such 4
5 risk reduction treatment efficiently now, in this population. The published evidence base demonstrates that such risk factor modification does not now occur in asymptomatic individuals with PAD. For this question, the Task Force would need to determine only if past cardiovascular event reduction trials have included patients with asymptomatic PAD and, if so, was cardiovascular ischemic event reduction achieved? We note that it is key for the Task Force to distinguish analyses of the benefits of preventing a cardiovascular ischemic event from the potential benefits of preventing new leg symptoms (which has never been a relevant national clinical question, nor the focus of clinical research). Key Question #5: What are the harms of treatment of screen-detected PAD? Do the harms of early treatment of PAD vary by subgroup (i.e., age, sex, race, risk factors)? As with Key Question #2, the Task Force should utilize published evidence, and not speculation, within its harm assessment methodology. First, the Task Force must determine if there is harm to non-detection and non-treatment of PAD by the lack of use of targeted screening. We believe that this is a key methodologic focus, as the clinical impact and health economic burden of non-detection has seemed overt. For the Task Force, the limited use of a simple, accurate, cost-effective, and safe ABI tool to detect PAD deprives patients (patient-focused care) and clinicians (in order to comply with current evidence-based care guidelines) of a large personal and societal opportunity to begin proven medication and lifestyle-based risk reduction therapies before a first heart attack or stroke occurs. This particular negative patient-focused outcome frame where a harm is achieved when patients are deprived access to a risk-free, extremely low-cost diagnostic method may be new to US Preventive Services Task Force. Were the Task Force to consider theoretical harms, we note that PAD is a disease with a latent phase (no recognized leg symptoms) that has proven extremely high short-term rates of non-fatal myocardial infarction, stroke, and death. The theoretical psychological harm of non-classification may almost certainly be greater than potential misclassification (though this has not been studied). As well, the potential misclassification harm could be (and is) easily managed by low cost, non-invasive testing, including use of a second ABI test. The other potential harms of screen-detected PAD (e.g., inappropriate use of medications, lifestyle interventions, diagnostic tests, or invasive procedures) are also theoretical and have no evidence base. While it is true that individuals with symptomatic PAD can be considered candidates for endovascular or surgical leg arterial interventions, screendetected individuals with PAD (by definition those without symptoms) are never 5
6 considered candidates for such procedures. The theoretical harms from inappropriate care delivery (use of contraindicated class III treatments) are managed in the United States by clinical care guidelines and by review of hospital privileges. Individuals with screen-detected, asymptomatic PAD receive standard treatment for atherosclerosis disease risk reduction (e.g. antiplatelet, statin, ACE inhibitor medications and risk reduction lifestyle interventions). Any harms associated with use of risk reduction interventions exist in this population regardless of whether treatment is triggered by the presence of classic risk factors or by an abnormal ABI. When medication and lifestyle risk reduction interventions are so used, it is proven that benefits far exceed harms, and are highly cost-effective; a US Preventive Services Task Force review of such treatments for PAD would be unlikely to conclude that atherosclerosis treatments have a distinct harm>risk ratio as compared to the robust atherosclerosis reduction evidence base. Therefore, any consideration of the harms associated with the treatment of screendetected PAD should only include standard atherosclerosis risk reduction (medication and lifestyle) treatments and need not consider potential harms of endovascular or surgical leg arterial interventions that, by definition, are outside of the accepted practice of medicine. In Summary: We appreciate the opportunity to comment on the Draft Research Plan. We look forward to working with you to ensure a successful assessment that might provide a major beneficial impact on national public health. If you have any questions, please feel free to contact this inter-societal work group via Mr. Joseph LaMountain, the Vascular Disease Foundation s Washington Representative, at Sincerely, Robert B. McLafferty, MD President of the Board Vascular Disease Foundation Gordon F. Tomaselli, MD, FAHA President American Heart Association David R. Holmes Jr., MD, FACC President American College or Cardiology Vivian Fonseca, MD President American Diabetes Association 6
7 References: 1. Sheehan P, Edmonds M, Januzzi J, et. al, Consensus Statement: Peripheral arterial disease in people with diabetes. Diabetes Care. 2003; 12; Diehm C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120: Fowkes FG. The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys. Int J Epidemiol. 1988;17: Feigelson HS, Criqui MH, Fronek A, et al. Screening for peripheral arterial disease: the sensitivity, specificity, and predictive value of noninvasive tests in a defined population. Am J Epidemiol. 1994;140: Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300: Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286: Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and comorbidity in 6,880 primary care patients: cross sectional study. Atherosclerosis. 2004;172: Resnick HE, Lindsay RS, McDermott MM, et al, Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation. 2004;109(6): Weatherley BD, Nelson JJ, Heiss G, et al. The association of the ankle-brachial index with incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study, BMC Cardiovasc Disord. 2007;7: Newman AB, Siscovick DS, Manolio TA, et al; Cardiovascular Heart Study (CHS) Collaborative Research Group. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Circulation. 1993;88: Kannel WB, Skinner JJ Jr, Schwartz MJ, et al. Intermittent claudication: incidence in the Framingham Study. Circulation 1970;41: Hirsch AT, Haskal ZJ, Hertzer NR, et al. American College of Cardiology and American Heart Association 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease. Circulation 2006; 113:e Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71: Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and comorbidity in 6,880 primary care patients: cross sectional study. Atherosclerosis. 2004;172: Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:
April 20, USPSTF Coordinator c/o USPSTF 540 Gaither Road Rockville, MD Dear Sir or Madam:
April 20, 2016 USPSTF Coordinator c/o USPSTF 540 Gaither Road Rockville, MD 20850 Dear Sir or Madam: Thank you for the opportunity to comment on the Draft Research Plan for Peripheral Artery Disease in
More informationUSWR 23: Outcome Measure: Non Invasive Arterial Assessment of patients with lower extremity wounds or ulcers for determination of healing potential
USWR 23: Outcome Measure: Non Invasive Arterial Assessment of patients with lower extremity wounds or ulcers for determination of healing potential MEASURE STEWARD: The US Wound Registry [Note: This measure
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Peripheral arterial disease Potential output:
More informationEarly Identification of PAD: Evidence to Refute USPSTF Position on Screening
Early Identification of PAD: Evidence to Refute USPSTF Position on Screening Mehdi H. Shishehbor, DO, MPH, PhD Director Endovascular Services Interventional Cardiology & Vascular Medicine Department of
More informationTreatment Strategies For Patients with Peripheral Artery Disease
Treatment Strategies For Patients with Peripheral Artery Disease Presented by Schuyler Jones, MD Duke University Medical Center & Duke Clinical Research Institute AHRQ Comparative Effectiveness Review
More informationGoals of Screening Programs. What is Vascular Screening? Assumptions Regarding the Potential Benefits of Screening Programs PAD
Conflict of Interest Disclosure (Relationships with Industry) An Epidemic of : The Debate Over Population Screening Membership on an advisory board, consultant, or recipient of a research grant from the
More informationAnkle brachial index performance among internal medicine residents
Ankle brachial index performance among internal medicine residents Vascular Medicine 15(2) 99 105 The Author(s) 2010 Reprints and permission: http://www. sagepub.co.uk/journalspermission.nav DOI: 10.1177/1358863X09356015
More informationPeripheral Arterial Disease (PAD): Presentation, Diagnosis, and Treatment
Peripheral Arterial Disease (PAD): Presentation, Diagnosis, and Treatment Prepared and Presented by Jon Manocchio, Pharm D Blanchard Valley Hospital October 2011 Introduction PAD is a condition that is
More informationIntroduction. Risk factors of PVD 5/8/2017
PATHOPHYSIOLOGY AND CLINICAL FEATURES OF PERIPHERAL VASCULAR DISEASE Dr. Muhamad Zabidi Ahmad Radiologist and Section Chief, Radiology, Oncology and Nuclear Medicine Section, Advanced Medical and Dental
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More informationJoshua A. Beckman, MD. Brigham and Women s Hospital
Peripheral Vascular Disease: Overview, Peripheral Arterial Obstructive Disease, Carotid Artery Disease, and Renovascular Disease as a Surrogate for Coronary Artery Disease Joshua A. Beckman, MD Brigham
More informationTABLE OF CONTENTS. 2. LOWER EXTREMITY PERIPHERAL ARTERIAL DISEASE 2.1. Epidemiology Risk Factors
LOWER EXTREMITY PAD The following is one of three extracted sections lower extremity, renal/mesenteric, and abdominal aortic of the ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral
More informationPeripheral Artery Disease Role of Exercise, Endovascular and Surgical Options
Peripheral Artery Disease Role of Exercise, Endovascular and Surgical Options Jeffrey W. Olin, D.O., F.A.C.C., F.A.H.A. Professor of Medicine (Cardiology) Director of Vascular Medicine & the Vascular Diagnostic
More informationIs the Ankle-Brachial Index a Useful Screening Test for Subclinical Atherosclerosis in Asymptomatic, Middle-Aged Adults?
Is the Ankle-Brachial Index a Useful Screening Test for Subclinical Atherosclerosis in Asymptomatic, Middle-Aged Adults? Rachael A. Wyman, MD; Jon G. Keevil, MD; Kjersten L. Busse, RN, MSN; Susan E. Aeschlimann,
More informationJohn E. Campbell, MD. Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division
John E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division John Campbell, MD For the 12 months preceding this CME activity,
More informationPrevalence, Progression and Associated Risk Factors of Asymptomatic Peripheral Arterial Disease
ORIGINAL PAPER ORIGINAL PAPER The ANNALS of AFRICAN SURGERY www.annalsofafricansurgery.com Prevalence, Progression and Associated Risk Factors of Asymptomatic Peripheral Arterial Disease Nikita Mehta 1,
More informationNational Clinical Conference 2018 Baltimore, MD
National Clinical Conference 2018 Baltimore, MD No relevant financial relationships to disclose Wound Care Referral The patient has been maximized from a vascular standpoint. She has no other options.
More informationACC NY Cardiovascular Symposium
ACC NY Cardiovascular Symposium Peripheral Vascular Disease: Watch the Heart and the Brain Evolving Role of Exercise, ACE-Inhibitors, Interventional and Surgical Options Mark A. Creager, M.D President,
More informationPAD Characterization Within A Healthcare System" RAPID Face-to-Face Meeting Schuyler Jones, MD September 14, 2016
PAD Characterization Within A Healthcare System" RAPID Face-to-Face Meeting Schuyler, MD September 14, 2016 Interventional Cardiology and Cath Labs Disclosures Research Grants: Agency for Healthcare Research
More informationPERIPHERAL ARTERIAL DISEASE (PAD); Frequency in diabetics.
PERIPHERAL ARTERIAL DISEASE (PAD); Frequency in diabetics. ORIGINAL PROF-2084 Dr. Qaiser Mahmood, Dr. Nasreen Siddique, Dr. Affan Qaiser ABSTRACT Objectives: (1) To determine the frequency of PAD in diabetic
More informationThe Accuracy of a Volume Plethysmography System as Assessed by Contrast Angiography
Research imedpub Journals http://www.imedpub.com/ DOI: 10.21767/2572-5483.100036 Journal of Preventive Medicine The Accuracy of a Volume Plethysmography System as Assessed by Contrast Angiography Andrew
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationLarry Diaz, MD, FSCAI Mehdi H. Shishehbor, DO, FSCAI
PAD Diagnosis Larry Diaz, MD, FSCAI Metro Health / University of Michigan Health, Wyoming, MI Mehdi H. Shishehbor, DO, FSCAI University Hospitals Harrington Heart & Vascular Institute, Cleveland, OH PAD:
More informationCase Study: Chris Arden. Peripheral Arterial Disease
Case Study: Chris Arden Peripheral Arterial Disease Patient Presentation Diane is a 65-year-old retired school teacher She complains of left calf pain when walking 50 metres; the pain goes away after she
More informationAmputation as a Last Resort A Multidisciplinary Approach to Limb Salvage
Amputation as a Last Resort A Multidisciplinary Approach to Limb Salvage George L. Adams, MD, MHS, MBA, FACC, FSCAI Clinical Associate Professor of Medicine University of North Carolina Health System Director
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationDapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58
Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58 Marc P. Bonaca MD MPH for the DECLARE TIMI 58 Investigators American College of Cardiology March 2019
More informationAnkle Brachial Index as a Marker of Atherosclerosis in Chinese Patients with High Cardiovascular Risk
23 Original Article Hypertens Res Vol.29 (2006) No.1 p.23-28 Ankle Brachial Index as a Marker of Atherosclerosis in Chinese Patients with High Cardiovascular Risk Buaijiaer HASIMU 1), Jue LI 1), Tomohiro
More informationClinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease
Cronicon OPEN ACCESS EC NEUROLOGY Research Article Clinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease Jin Ok Kim, Hyung-IL Kim, Jae Guk Kim, Hanna Choi, Sung-Yeon
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationPrevalence of Abnormal Ankle Brachial Index in Iraqi Patients with Systemic Lupus Erythematosus
ANKLE THE IRAQI BRACHIAL POSTGRADUATE INDEX MEDICAL IN SYSTEMIC JOURNAL LUPUS ERYTHEMATOSUS Prevalence of Abnormal Ankle Brachial Index in Iraqi Patients with Systemic Lupus Erythematosus Ziad S. Al-Rawi*,
More informationORIGINAL INVESTIGATION. The Long-term Prognostic Value of the Resting and Postexercise Ankle-Brachial Index
ORIGINAL INVESTIGATION The Long-term Prognostic Value of the Resting and Postexercise Ankle-Brachial Index Harm H. H. Feringa, MD; Jeroen J. J. Bax, MD, PhD; Virginie H. van Waning, MD; Eric Boersma, PhD;
More informationEvidence Synthesis Number 100
Evidence Synthesis Number 100 The Ankle Brachial Index for Peripheral Artery Disease Screening and Cardiovascular Disease Prediction in Asymptomatic Adults: A Systematic Evidence Review for the U.S. Preventive
More informationORIGINAL INVESTIGATION. Exertional Leg Symptoms Other Than Intermittent Claudication Are Common in Peripheral Arterial Disease
ORIGINAL INVESTIGATION Exertional Leg Symptoms Other Than Intermittent Claudication Are Common in Peripheral Arterial Disease Mary McGrae McDermott, MD; Shruti Mehta, BA; Philip Greenland, MD Background:
More informationScreening for Peripheral Artery Disease Using the Ankle-Brachial Index: An Updated Systematic Review for the U.S. Preventive Services Task Force
Evidence Synthesis Number 165 Screening for Peripheral Artery Disease Using the Ankle-Brachial Index: An Updated Systematic Review for the U.S. Preventive Services Task Force Prepared for: Agency for Healthcare
More informationJune 21, Harry Feliciano, MD, MPH Senior Medical Director Part A Policy Palmetto GBA PO Box (JM) AG-275 Columbia, SC 29202
June 21, 2018 Harry Feliciano, MD, MPH Senior Medical Director Part A Policy Palmetto GBA PO Box 100238 (JM) AG-275 Columbia, SC 29202 Submitted electronically: A.Policy@PalmettoGBA.com RE: Proposed LCD
More informationLimitation of the resting ankle brachial index in symptomatic patients with peripheral arterial disease
Limitation of the resting ankle brachial index in symptomatic patients with peripheral arterial disease Russell Stein a, Ingrid Hriljac a, Jonathan L Halperin a, Susan M Gustavson a, Victoria Teodorescu
More informationWorld s Fastest Ankle-Brachial Index Screening Device
World s Fastest Ankle-Brachial Index Screening Device Accurate and objective Peripheral Arterial Disease diagnosis E S S E N T I A L T O H E A LT H NOTE: Brošura - A4 format na poli A3 What is Peripheral
More informationPeripheral Arterial Disease Management A Practical Guide for Internists. EFIM Vascular Working Group
2 Peripheral Arterial Disease Management A Practical Guide for Internists EFIM Vascular Working Group 1 Peripheral arterial disease (PAD) is a growing concern among our aging population. More than 27 million
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence
More informationPredictors of an abnormal postexercise ankle brachial index: Importance of the lowest ankle pressure in calculating the resting ankle brachial index
Received: 14 May 2017 Revised: 18 August 2017 Accepted: 4 September 2017 DOI: 10.1002/clc.22808 CLINICAL INVESTIGATIONS Predictors of an abnormal postexercise ankle brachial index: Importance of the lowest
More informationImaging for Peripheral Vascular Disease
Imaging for Peripheral Vascular Disease James G. Jollis, MD Director, Rex Hospital Cardiovascular Imaging Imaging for Peripheral Vascular Disease 54 year old male with exertional calf pain in his right
More informationInternational Journal of Pharma and Bio Sciences
Research Article Nursing International Journal of Pharma and Bio Sciences ISSN 0975-6299 EFFECTIVENESS OF ALLEN BUERGER EXERCISE IN PREVENTING PERIPHERAL ARTERIAL DISEASE AMONG PEOPLE WITH TYPE II DIABETES
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationIn December of 1999, the Healthcare Research and Quality. Special Report
Special Report The United States Preventive Services Task Force Recommendation Statement on Screening for Peripheral Arterial Disease More Harm Than Benefit? Joshua A. Beckman, MD, MS; Michael R. Jaff,
More informationRegistry Assessment of Peripheral Interventional Devices (RAPID)
Registry Assessment of Peripheral Interventional Devices (RAPID) Adding Data Sources May 2, 2018 W. Schuyler Jones, MD Duke Clinical Research Institute Duke Heart Center Disclosures Research Grants: Agency
More informationMORTALITY AND MORBIDITY RISK FROM CAROTID ARTERY ATHEROSCLEROSIS. 73 year old NS right-handed male applicant for $1 Million life insurance
MORTALITY AND MORBIDITY RISK FROM CAROTID ARTERY ATHEROSCLEROSIS October 17, 2012 AAIM Triennial Conference, San Diego Robert Lund, MD What Is The Risk? 73 year old NS right-handed male applicant for $1
More informationMaximally Invasive Vascular Surgery for the Treatment of Critical Limb Ischemia
Maximally Invasive Vascular Surgery for the Treatment of Critical Limb Ischemia Traci A. Kimball, MD Department of Surgery Grand Rounds Septemember 13, 2010 Overview Defining Critical Limb Ischemia Epidemiology
More informationMEDICAL POLICY SUBJECT: CORONARY CALCIUM SCORING
MEDICAL POLICY PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationMORTALITY AND MORBIDITY RISK FROM CAROTID ARTERY ATHEROSCLEROSIS. 73 year old NS right-handed male applicant for $1 Million Life Insurance
MORTALITY AND MORBIDITY RISK FROM CAROTID ARTERY ATHEROSCLEROSIS October 17, 2012 AAIM Triennial Conference, San Diego Robert Lund, MD What Is The Risk? 73 year old NS right-handed male applicant for $1
More informationACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 Performance Measures for Adults With Peripheral Artery Disease
Journal of the American College of Cardiology Vol. 56, No. 25, 2010 2010 by the American College of Cardiology Foundation and the American Heart Association, Inc. ISSN 0735-1097/$36.00 Published by Elsevier
More informationGuidelines for Management of Peripheral Arterial Disease
Guidelines for Management of Peripheral Arterial Disease Subhash Banerjee, MD, FACC, FSCAI Professor of Medicine, Univ. of Texas Southwestern Medical Center Chief, Division of Cardiology, VA North Texas
More informationBangladesh Journal of Medical Science Vol. 15 No. 04 October 16
Bangladesh Journal of Medical Science Vol. 15 No. 04 October 16 Original article The prevalence of peripheral artery disease by using ankle brachial index in hypertensive patients Singal KK 1, Singal N
More informationGeneral introduction. Chapter 1
Chapter 1 Despite a better understanding of the aetiology and pathophysiology of atherothrombotic vascular disease, and the availability of effective treatment modalities, the burden of vascular disease
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationEvidence Synthesis Number 88
Evidence Synthesis Number 88 Screening Asymptomatic Adults for Coronary Heart Disease With Resting or Exercise Electrocardiography: Systematic Review to Update the 2004 U.S. Preventive Services Task Force
More informationObservations on US CVD Prevention Guidelines. Donald M. Lloyd-Jones, MD ScM FACC FAHA
Observations on US CVD Prevention Guidelines Donald M. Lloyd-Jones, MD ScM FACC FAHA What are Guidelines? Evidence Base for Guidelines Tricoci, JAMA 2009 Evidence Base for Guidelines Tricoci, JAMA 2009
More informationWhat s New in the Management of Peripheral Arterial Disease
What s New in the Management of Peripheral Arterial Disease Sibu P. Saha, MD, MBA Professor of Surgery Chairman, Directors Council Gill Heart Institute University of Kentucky Lexington, KY Disclosure My
More informationQuality ID #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Quality ID #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationPrevention of Heart Disease: The New Guidelines
Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015
More informationNorthwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?
Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA Senior Associate Dean Chair, Department of Preventive
More informationIs there an association between atherosclerosis and chronic venous disease?
Is there an association between atherosclerosis and chronic venous disease? Karel Roztocil, IKEM, Praha Hungarian Society of Angiology and Vascular Surgery Congress, Szombathely 2017 Disclosure Nothing
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: July 20, 2017 Next
More informationGENERAL COMMENTS. The Task Force Process Should be Fully Open, Balanced and Transparent
December 9, 2013 Submitted Electronically United States Preventive Services Task Force c/o Dr. Robert Cosby Agency for Healthcare Research and Quality 540 Gaither Road Rockville, MD 20850 RE: USPSTF Draft
More informationImaging in the Evaluation of Coronary Artery Disease and Abdominal Aortic Aneurysm
Imaging in the Evaluation of Coronary Artery Disease and Abdominal Aortic Aneurysm Mark J. Sands, MD Vice Chairman, Imaging Institute Clinical Operations and Quality Objectives Review of available radiologic
More informationHypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis
Cryoplasty or Conventional Balloon Post-dilation of Nitinol Stents For Revascularization of Peripheral Arterial Segments Background: Diabetes mellitus is associated with increased risk of in-stent restenosis
More informationDue to Perimed s commitment to continuous improvement of our products, all specifications are subject to change without notice.
A summary Disclaimer The information contained in this document is intended to provide general information only. It is not intended to be, nor does it constitute, medical advice. Under no circumstances
More informationSummary HTA. HTA-Report Summary
Summary HTA HTA-Report Summary Prognostic value, clinical effectiveness and cost-effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events Schnell-Inderst
More information2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary
2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth
More informationWhen to screen for PAD? Prof. Dr.Tine De Backer Prof. Dr. Jean-Claude Wautrecht
When to screen for PAD? Prof. Dr.Tine De Backer Prof. Dr. Jean-Claude Wautrecht How do we define asymptomatic PAD? A. ABI < 1 B. ABI < 0.9 C. ABI < 0.8 D. ABI > 1 How do we define asymptomatic PAD? A.
More informationLIBERTY 360 Study. 15-Jun-2018 Data 1. Olinic Dm, et al. Int Angiol. 2018;37:
LIBERTY 360 Study LIBERTY is a prospective, observational, multi-center study to evaluate procedural and long-term clinical and economic outcomes of endovascular device interventions in patients with symptomatic
More informationVDF and The Burden of Vascular Disease
VESSEL: The Annual Meeting of the VDF September 23,2012 VDF and The Burden of Vascular Disease David P. Faxon MD President Elect VDF Vice Chair of Medicine Brigham and Women s Hospital Disclosures: Boston
More informationAN ASSESSMENT OF INTER-RATER RELIABILITY IN THE TREATMENT OF CAROTID ARTERY STENOSIS
Pak Heart J ORIGINAL ARTICLE AN ASSESSMENT OF INTER-RATER RELIABILITY IN THE TREATMENT OF CAROTID ARTERY STENOSIS 1 2 3 4 5 Abhishek Nemani, Arshad Ali, Arshad Rehan, Ali Aboufaris, Jabar Ali 1-4 Guthrie
More informationPeripheral Arterial Occlusive Disease- The Challenge in patients with diabetes
Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes Ashok Handa Reader in Surgery and Consultant Surgeon Nuffield Department of Surgery University of Oxford Introduction Vascular
More informationThe Ankle- Brachial Pressure Index AS A Predictor of Coronary. Artery Disease Severity
Original Article The Ankle- Brachial Pressure Index AS A Predictor of Coronary * Haider J. Al Ghizzi** Shakir M. Muhammed** MBChB, FRCP, FACC MBChB, CABM, FICMS MBChB, FICMS Fac Med Baghdad 2009; Vol.
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More informationLDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial
LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial Marc P. Bonaca, Patrice Nault, Robert P. Giugliano, Anthony C. Keech, Armando
More informationUsing the ankle-brachial index to diagnose peripheral artery disease and assess cardiovascular risk
REVIEW CME CREDIT EDUCATIONAL OBJECTIVE: Readers will use the ankle-brachial index to detect peripheral artery disease ESTHER S. H. KIM, MD, MPH Vascular Medicine Section, Department of Cardiovascular
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationObjectives. Abdominal Aortic Aneuryms 11/16/2017. The Vascular Patient: Diagnosis and Conservative Treatment
The Vascular Patient: Diagnosis and Conservative Treatment Ferrell-Duncan Clinic Zachary C. Schmittling, M.D., F.A.C.S. Vascular and General Surgery Ferrell-Duncan Clinic Cox Health Systems Objectives
More informationWorld s Fastest Ankle-Brachial Index Screening Device
World s Fastest Ankle-Brachial Index Screening Device Accurate and objective Peripheral Arterial Disease diagnosis From secondary to primary healthcare with the help of technology. MESI founders identified
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationConsensus document: Screening and Prevention of Atrial Fibrillation
Consensus document: Screening and Prevention of Atrial Fibrillation Yong-Seog Oh, M.D.,Ph.D. Division of Cardiology, Department of Internal Medicine, Seoul St. Mary s Hospital, College of Medicine, The
More informationJournal of American Science 2014;10(8)
Role of Doppler Ultrasound and Peripheral Angiography (as a Diagnostic Modality of Atherosclerosis) in Combination with Conventional Atherosclerosis Risk Factors in Coronary Artery Disease Prediction Hussein
More informationPeripheral Arterial Disease. Westley Smith MD Vascular Fellow
Peripheral Arterial Disease Westley Smith MD Vascular Fellow Background (per 10,000) Goodney P, et al. Regional intensity of vascular care and lower extremity amputation rates. JVS. 2013; 6: 1471-1480.
More informationPrognostic Significance of Declining Ankle-brachial Index Values in Patients with Suspected or Known Peripheral Arterial Disease
Eur J Vasc Endovasc Surg 34, 206e213 (2007) doi:10.1016/j.ejvs.2007.02.018, available online at http://www.sciencedirect.com on Prognostic Significance of Declining Ankle-brachial Index Values in Patients
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationDisclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.
Disclosures Prevention of Heart Disease: The New Guidelines No relevant disclosures Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationPeripheral Arterial Disease Extremity
Peripheral Arterial Disease Lower Extremity 05 Contributor Dr Steven Chong Advisors Dr Ashish Anil Dr Tay Jam Chin Introduction Risk Factors Clinical Presentation Classification History PHYSICAL examination
More informationThe Struggle to Manage Stroke, Aneurysm and PAD
The Struggle to Manage Stroke, Aneurysm and PAD In this article, Dr. Salvian examines the management of peripheral arterial disease, aortic aneurysmal disease and cerebrovascular disease from symptomatology
More informationJAPAN PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA PREVALENCE AND INCIDENCE
JAPAN PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA PREVALENCE AND INCIDENCE Mary L. Yost 404-520-6652 , LLC 23 Ridge Rd Beaufort SC 29907 Copyright Pending 2017 All rights reserved, including the
More informationTom Eisele, Benedikt M. Muenz, and Grigorios Korosoglou. Department of Cardiology & Vascular Medicine, GRN Hospital Weinheim, Weinheim, Germany
Case Reports in Vascular Medicine Volume 2016, Article ID 7376457, 4 pages http://dx.doi.org/10.1155/2016/7376457 Case Report Successful Endovascular Repair of an Iatrogenic Perforation of the Superficial
More informationPatient Brochure. Clearstream Technologies, Ltd. Moyne Upper Enniscorthy Co. Wexford, Ireland. PK Rev. 0 05/17
Patient Brochure Clearstream Technologies, Ltd. Moyne Upper Enniscorthy Co. Wexford, Ireland PK1411100 Rev. 0 05/17 LIFESTREAM Patient Brochure If you or a member of your family has been diagnosed with
More informationCase Report Successful Implantation of a Coronary Stent Graft in a Peripheral Vessel
Case Reports in Vascular Medicine Volume 2015, Article ID 725168, 4 pages http://dx.doi.org/10.1155/2015/725168 Case Report Successful Implantation of a Coronary Stent Graft in a Peripheral Vessel Alexander
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Pulse Oximetry as a Potential Screening Tool for Lower Extremity Arterial Disease in Asymptomatic Patients With Diabetes Mellitus G. Iyer Parameswaran, MD; Kathy Brand, RDMS, RVT;
More informationPrevention of MACROvascular Complications of Diabetes
Prevention of MACROvascular Complications of Diabetes Matt Bouchonville, MD, CDE Endocrinology Division University of New Mexico School of Medicine July 12, 2018 Conflicts of Interest None Objectives 1.
More information